cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28320945.v1
title: Peripheral magnetic stimulation for the treatment of fibromyalgia: a systematic review and meta-analysis

description: To systematically review and conduct a meta-analysis of studies on peripheral magnetic stimulation (PMS) for fibromyalgia (FM) treatment. MEDLINE, EMBASE, CENTRAL, CINHAL, Web of Science, and ProQuest databases were searched from inception to July 2023 for studies in adult patients with FM treated with PMS. Studies using transcranial magnetic stimulation were excluded. Six randomized controlled trials (RCTs) (<i>n</i> = 279 patients) were identified and included in the review. PMS regimens varied, ranging from 8 to 40 min per session over 3–84 days. All studies compared PMS to a visually and physically identical sham device without magnetic fields. Most of the included studies demonstrated positive findings for PMS on pain and functional outcomes. In our meta-analysis, PMS significantly reduced pain scores within 1–3 months (mean difference −1.86 on NRS, 95% confidence interval −2.85 to −0.87, <i>p</i> = 0.0002, I<sup>2</sup> = 68%, 4 studies [154 participants], low quality of evidence), but not at ≥3 months (low quality of evidence). Minimal adverse effects were reported. Evidence for PMS use in FM is encouraging for short-term benefit. However, heterogeneous patient populations, varied PMS regimens, and limited number of studies are important limitations. Large, high-quality RCTs are needed to confirm PMS benefits and to make definitive recommendations. PROSPERO Identifier is CRD42021235164. Fibromyalgia is a long-lasting condition that causes body-wide pain. This can make everyday activities difficult. This study looked at a treatment called peripheral magnetic stimulation (PMS) to see if it could help with fibromyalgia. The results showed that PMS can reduce pain by 16% to 55% over 1–3 months. It also helps people move and feel better overall. However, some studies found no big difference between PMS and placebo treatments. Therefore, PMS might not always work. Scientists think PMS can affect brain activity and blood flow. However, it is unclear how it does this. PMS might be a useful fibromyalgia treatment. More studies are needed to confirm how best to use it.
DOI: 10.6084/m9.figshare.29279332
title: Efficacy and safety of rimegepant 75 mg for acute treatment of migraine: a pooled analysis of four randomized, placebo-controlled trials

description: This pooled analysis of data from four randomized placebo-controlled trials summarizes the efficacy and safety of rimegepant for acute treatment of migraine. In all studies, participants were aged ≥18 years and had a ≥ 1-year history of migraine, two to eight migraine attacks of moderate or severe pain intensity per month, and attacks lasting 4–72 hours if untreated. Participants were provided with a single dose of rimegepant 75 mg or placebo to treat a single migraine attack of moderate or severe pain intensity within the next 45 days. Co-primary endpoints at 2 hours post-dose were pain freedom and freedom from the most bothersome symptom (MBS). Treatment comparisons utilized Mantel–Haenszel risk estimation with stratification by study and prophylactic migraine medication use randomization stratum; <i>p</i> values are nominal. On-treatment adverse events (AEs) were also assessed. Overall, 4,895 participants received rimegepant (<i>n</i> = 2,439) or placebo (<i>n</i> = 2,456). For the co-primary endpoints, the proportion of participants with pain freedom 2 hours post-dose (20.0% vs. 11.8%; <i>p</i> &lt; 0.0001) and MBS freedom 2 hours post-dose (40.2% vs. 29.2%; <i>p</i> &lt; 0.0001) was higher in the rimegepant vs. the placebo group. Rimegepant also demonstrated improvements over placebo in nearly all secondary and exploratory efficacy endpoints. AEs were reported in 11.1% and 9.6% of participants in the rimegepant and placebo groups, respectively. The only AE reported in &gt; 1% of participants was nausea (rimegepant = 1.4%, placebo = 1.3%). Severe AEs occurred in 0.3% and 0.1% of participants in the rimegepant and placebo groups, respectively. Serious AEs occurred in 0.1% of participants in both groups; none were deemed related to study treatment. In this pooled analysis of four randomized placebo-controlled trials, a single dose of rimegepant 75 mg demonstrated efficacy and a favorable safety profile for the acute treatment of a migraine attack with moderate or severe pain.
DOI: 10.6084/m9.figshare.29279332.v2
title: Efficacy and safety of rimegepant 75 mg for acute treatment of migraine: a pooled analysis of four randomized, placebo-controlled trials

description: This pooled analysis of data from four randomized placebo-controlled trials summarizes the efficacy and safety of rimegepant for acute treatment of migraine. In all studies, participants were aged ≥18 years and had a ≥ 1-year history of migraine, two to eight migraine attacks of moderate or severe pain intensity per month, and attacks lasting 4–72 hours if untreated. Participants were provided with a single dose of rimegepant 75 mg or placebo to treat a single migraine attack of moderate or severe pain intensity within the next 45 days. Co-primary endpoints at 2 hours post-dose were pain freedom and freedom from the most bothersome symptom (MBS). Treatment comparisons utilized Mantel–Haenszel risk estimation with stratification by study and prophylactic migraine medication use randomization stratum; <i>p</i> values are nominal. On-treatment adverse events (AEs) were also assessed. Overall, 4,895 participants received rimegepant (<i>n</i> = 2,439) or placebo (<i>n</i> = 2,456). For the co-primary endpoints, the proportion of participants with pain freedom 2 hours post-dose (20.0% vs. 11.8%; <i>p</i> &lt; 0.0001) and MBS freedom 2 hours post-dose (40.2% vs. 29.2%; <i>p</i> &lt; 0.0001) was higher in the rimegepant vs. the placebo group. Rimegepant also demonstrated improvements over placebo in nearly all secondary and exploratory efficacy endpoints. AEs were reported in 11.1% and 9.6% of participants in the rimegepant and placebo groups, respectively. The only AE reported in &gt; 1% of participants was nausea (rimegepant = 1.4%, placebo = 1.3%). Severe AEs occurred in 0.3% and 0.1% of participants in the rimegepant and placebo groups, respectively. Serious AEs occurred in 0.1% of participants in both groups; none were deemed related to study treatment. In this pooled analysis of four randomized placebo-controlled trials, a single dose of rimegepant 75 mg demonstrated efficacy and a favorable safety profile for the acute treatment of a migraine attack with moderate or severe pain.
DOI: 10.6084/m9.figshare.29609627
title: Deciphering the potential of the lactate dehydrogenase-to-albumin ratio as a prognostic biomarker in malignancy: a systematic review and meta-analysis

description: Recent studies have indicated that the pretreatment lactate dehydrogenase (LDH)-to-albumin ratio (LAR) serves as a comprehensive prognostic biomarker. However, no comprehensive meta-analysis that assesses its prognostic role in various malignancies has been conducted. This study aimed to summarize the current evidence on the prognostic value of the LAR in patients with malignancies. A systematic literature search was conducted before 1 October 2024 in six databases. Quantitative analysis with random-effect meta-analysis was employed for generating the pooled estimates of survival outcomes (overall, progression-free, disease-free, and relapse-free survivals [OS, PFS, DFS, and RFS, respectively]). A meta-analysis of 19 retrospective studies encompassing 11,088 patients with cancer demonstrated the significant association between a high LAR and poorer OS (hazard ratio [HR] = 1.67 [1.37–2.05], I<sup>2</sup> = 84%). Patients with solid tumors exhibited a significantly higher risk of poorer OS and PFS (HR = 1.73 [1.44–2.06], I<sup>2</sup> = 84%; HR = 1.43 [1.11–1.84], I<sup>2</sup> = 75%). Subgroup analysis revealed that digestive system tumors were associated with an increased risk of poor OS (HR = 2.15), including oral cancer (HR = 5.14), esophageal carcinoma (HR = 1.85), hepatocellular carcinoma (HR = 1.90), and colorectal cancer (HR = 2.12). Furthermore, nasopharyngeal carcinoma was associated with poorer OS and PFS (HR = 1.62 [1.36–1.92]; HR = 1.60 [1.20–2.14], I<sup>2</sup> &lt; 50%). This study demonstrated the significant association between an elevated pretreatment LAR and poorer survival outcomes in malignancies, particularly in solid and digestive system tumors. These findings support the LAR as a potential prognostic biomarker, warranting further validation in diverse populations with standardized cutoff values.
DOI: 10.6084/m9.figshare.29609627.v1
title: Deciphering the potential of the lactate dehydrogenase-to-albumin ratio as a prognostic biomarker in malignancy: a systematic review and meta-analysis

description: Recent studies have indicated that the pretreatment lactate dehydrogenase (LDH)-to-albumin ratio (LAR) serves as a comprehensive prognostic biomarker. However, no comprehensive meta-analysis that assesses its prognostic role in various malignancies has been conducted. This study aimed to summarize the current evidence on the prognostic value of the LAR in patients with malignancies. A systematic literature search was conducted before 1 October 2024 in six databases. Quantitative analysis with random-effect meta-analysis was employed for generating the pooled estimates of survival outcomes (overall, progression-free, disease-free, and relapse-free survivals [OS, PFS, DFS, and RFS, respectively]). A meta-analysis of 19 retrospective studies encompassing 11,088 patients with cancer demonstrated the significant association between a high LAR and poorer OS (hazard ratio [HR] = 1.67 [1.37–2.05], I<sup>2</sup> = 84%). Patients with solid tumors exhibited a significantly higher risk of poorer OS and PFS (HR = 1.73 [1.44–2.06], I<sup>2</sup> = 84%; HR = 1.43 [1.11–1.84], I<sup>2</sup> = 75%). Subgroup analysis revealed that digestive system tumors were associated with an increased risk of poor OS (HR = 2.15), including oral cancer (HR = 5.14), esophageal carcinoma (HR = 1.85), hepatocellular carcinoma (HR = 1.90), and colorectal cancer (HR = 2.12). Furthermore, nasopharyngeal carcinoma was associated with poorer OS and PFS (HR = 1.62 [1.36–1.92]; HR = 1.60 [1.20–2.14], I<sup>2</sup> &lt; 50%). This study demonstrated the significant association between an elevated pretreatment LAR and poorer survival outcomes in malignancies, particularly in solid and digestive system tumors. These findings support the LAR as a potential prognostic biomarker, warranting further validation in diverse populations with standardized cutoff values.
DOI: 10.6084/m9.figshare.29279332.v1
title: Efficacy and safety of rimegepant 75 mg for acute treatment of migraine: a pooled analysis of four randomized, placebo-controlled trials

description: This pooled analysis of data from four randomizedplacebo-controlled trials summarizes the efficacy and safety of rimegepant foracute treatment of migraine. In all studies, participants were aged ≥18 years and had a ≥ 1-year history of migraine,two to eight migraine attacks of moderate or severe pain intensity per month,and attacks lasting 4–72 hoursif untreated. Participants were provided a single dose of rimegepant 75 mg orplacebo to treat a single migraine attack of moderate or severe pain intensitywithin the next 45 days. Co-primary endpoints at 2 hours post-dose were painfreedom and freedom from the most bothersome symptom (MBS). Treatmentcomparisons utilized Mantel-Haenszel risk estimation with stratification bystudy and prophylactic migraine medication use randomization stratum; <i>p</i>values are nominal. On-treatment adverse events (AEs) were also assessed. Overall, 4,895 participants received rimegepant (<i>n</i> = 2,439) orplacebo (<i>n</i> = 2,456). For the co-primary endpoints, the proportions ofparticipants with pain freedom 2 hours post-dose (20.0% vs. 11.8%; <i>p</i> &lt; 0.0001)and MBS freedom 2 hours post-dose (40.2% vs. 29.2%; <i>p</i> &lt; 0.0001) were higherin the rimegepant vs. the placebo group. Rimegepant also demonstratedimprovements over placebo in nearly all secondary and exploratory efficacyendpoints. AEs were reported in 11.1% and 9.6% of participants in therimegepant and placebo groups, respectively. The only AE reported in &gt; 1% ofparticipants was nausea (rimegepant = 1.4%, placebo = 1.3%). Severe AEs occurred in0.3% and 0.1% of participants in the rimegepant and placebo groups,respectively. Serious AEs occurred in 0.1% of participants in both groups; nonewere deemed related to study treatment. In this pooled analysis of four randomized placebo-controlledtrials, a single dose of rimegepant 75 mg demonstrated efficacy and a favorablesafety profile for the acute treatment of a migraine attack with moderate orsevere pain.
DOI: 10.15468/dl.9km26h
title: Occurrence Download

description: A dataset containing 61 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Invertebrates from the Kendara Valley (Karkaraly National Park, Kazakhstan)"
 ]
}

 The dataset includes 61 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038450-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.s8f4kb
title: Occurrence Download

description: A dataset containing 13376 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Microbotryum",
 "HasCoordinate is true"
 ]
}

 The dataset includes 13376 records from 243 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038449-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.u396k7
title: Occurrence Download

description: A dataset containing 578 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Soil invertebrates collected during the IX Field School on Soil Zoology and Ecology for Young Scientists (Karkaraly National Park, Kazakhstan)"
 ]
}

 The dataset includes 578 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038451-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.cbu2ng
title: Occurrence Download

description: A dataset containing 315 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is one of (Specimen, Living Specimen)",
 "Country is Korea (Democratic People’s Republic of)",
 "DatasetKey is Herbarium Berolinense, Berlin (B)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 315 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038452-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17611404
title: Underwater images collected by a Kite surf in Pointe-Esny, Mauritius - 2018-03-18

description: This dataset was collected by a Kite surf in Pointe-Esny, Mauritius - 2018-03-18. 

            Underwater or aerial images collected by scientists or citizens can have a wide variety of use for science, management, or conservation.
            These images can be annotated and shared to train IA models which can in turn predict the objects on the images.
            We provide a set of tools (hardware and software) to collect marine data, predict species or habitat, and provide maps.

            This dataset is part of larger collection referencing numerous underwater and aerial images Seatizen Altas. 
            Methods, tools and scientific objectives are also described in a dedicated data paper.

            
                
                                       
                
                
 GPS information: 

                GPX file from Garmin watch.
            
                    
                

                
            

            
 Generic folder structure 
            
            YYYYMMDD_COUNTRYCODE-optionalplace_device_session-number 
            ├── DCIM :  folder to store videos and photos depending on the media collected. 
            ├── GPS :  folder to store any positioning related file. If any kind of correction is possible on files (e.g. Post-Processed Kinematic thanks to rinex data) then the distinction between device data and base data is made. If, on the other hand, only device position data are present and the files cannot be corrected by post-processing techniques (e.g. gpx files), then the distinction between base and device is not made and the files are placed directly at the root of the GPS folder. 
            │   ├── BASE :  files coming from rtk station or any static positioning instrument. 
            │   └── DEVICE : files coming from the device. 
            ├── METADATA : folder with general information files about the session. 
            ├── PROCESSED_DATA : contain all the folders needed to store the results of the data processing of the current session. 
            │   ├── BATHY :  output folder for bathymetry raw data extracted from mission logs. 
            │   ├── FRAMES :  output folder for georeferenced frames extracted from DCIM videos. 
            │   ├── IA :  destination folder for image recognition predictions. 
            │   └── PHOTOGRAMMETRY :  destination folder for reconstructed models in photogrammetry. 
            └── SENSORS : folder to store files coming from other sources (bathymetry data from the echosounder, log file from the autopilot,  mission plan etc.).       
            

            
 Software 
            All the raw data was processed using our worflow. All predictions were generated by our inference pipeline. You can find all the necessary scripts to download this data in this repository. Enjoy your data with SeatizenDOI!
DOI: 10.5281/zenodo.17626967
title: Underwater images collected by a Kite surf in Pointe-Esny, Mauritius - 2018-03-18

description: This dataset was collected by a Kite surf in Pointe-Esny, Mauritius - 2018-03-18. 

            Underwater or aerial images collected by scientists or citizens can have a wide variety of use for science, management, or conservation.
            These images can be annotated and shared to train IA models which can in turn predict the objects on the images.
            We provide a set of tools (hardware and software) to collect marine data, predict species or habitat, and provide maps.

            This dataset is part of larger collection referencing numerous underwater and aerial images Seatizen Altas. 
            Methods, tools and scientific objectives are also described in a dedicated data paper.

            
                
                                       
                
                
 GPS information: 

                GPX file from Garmin watch.
            
                    
                

                
            

            
 Generic folder structure 
            
            YYYYMMDD_COUNTRYCODE-optionalplace_device_session-number 
            ├── DCIM :  folder to store videos and photos depending on the media collected. 
            ├── GPS :  folder to store any positioning related file. If any kind of correction is possible on files (e.g. Post-Processed Kinematic thanks to rinex data) then the distinction between device data and base data is made. If, on the other hand, only device position data are present and the files cannot be corrected by post-processing techniques (e.g. gpx files), then the distinction between base and device is not made and the files are placed directly at the root of the GPS folder. 
            │   ├── BASE :  files coming from rtk station or any static positioning instrument. 
            │   └── DEVICE : files coming from the device. 
            ├── METADATA : folder with general information files about the session. 
            ├── PROCESSED_DATA : contain all the folders needed to store the results of the data processing of the current session. 
            │   ├── BATHY :  output folder for bathymetry raw data extracted from mission logs. 
            │   ├── FRAMES :  output folder for georeferenced frames extracted from DCIM videos. 
            │   ├── IA :  destination folder for image recognition predictions. 
            │   └── PHOTOGRAMMETRY :  destination folder for reconstructed models in photogrammetry. 
            └── SENSORS : folder to store files coming from other sources (bathymetry data from the echosounder, log file from the autopilot,  mission plan etc.).       
            

            
 Software 
            All the raw data was processed using our worflow. All predictions were generated by our inference pipeline. You can find all the necessary scripts to download this data in this repository. Enjoy your data with SeatizenDOI!
DOI: 10.15468/dl.2sdyax
title: Occurrence Download

description: A dataset containing 100 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((79.65267 29.64738,79.83748 29.64435,79.83546 29.78866,79.65171 29.7916,79.65267 29.64738))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Insecta"
 ]
}

 The dataset includes 100 records from 4 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038453-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.d53csg
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Zundeliomyces",
 "HasCoordinate is true"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038454-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.u48qgh
title: Occurrence Download

description: A dataset containing 50 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Aurantiosporium",
 "HasCoordinate is true"
 ]
}

 The dataset includes 50 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038455-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.34740/kaggle/dsv/13761258
title: Peer-to-Peer Boliviano (BOB) Exchange Data
DOI: 10.15468/dl.rguzap
title: Occurrence Download

description: A dataset containing 546 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "GadmGid is CHN.28_1",
 "TaxonKey is Zygophyllum"
 ]
}

 The dataset includes 546 records from 11 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038456-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.9gjkus
title: Occurrence Download

description: A dataset containing 578 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Ustilentyloma",
 "HasCoordinate is true"
 ]
}

 The dataset includes 578 records from 49 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038457-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.